Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ASPH | Q12797 | 1/20 | 0.31 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1021971 | 1.00 | NAPRT (0.32) | NAPRTKDM4EASPHKDM8 | |
| SCHEMBL132690 | 0.97 | — | — | |
| Water SCHEMBL8567684 | 0.94 | NAPRT (0.32) | NAPRTKDM4EASPHKDM8 | |
| SCHEMBL9515703 | 0.94 | NAPRT (0.32) | NAPRTKDM4EASPHKDM8 | |
| SCHEMBL1300770 | 0.84 | NAPRT (0.31) | NAPRTKDM4EASPHKDM8 | |
| Ether SCHEMBL8567683 | 0.80 | HPGD (0.32) | — | |
| Hydrochloric Acid SCHEMBL16992907 | 0.74 | NCF1 (0.37) | NAPRTKDM4E | |
| SCHEMBL5178519 | 0.72 | — | — | |
| SCHEMBL6347184 | 0.70 | — | — | |
| SCHEMBL2372078 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8679535-B2 | Sustained release matrix systems for highly soluble drugs | ENDO PHARMACEUTICALS INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-31 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CHILDREN'S MEDICAL CENTER CORPORATION | 2025-04-22 | — | — | US | disclosed |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240307372-A1 | COMPOSITIONS AND METHODS TO IMPROVE BENEFIT OF SUBOPTIMALLY ADMINISTERED THERAPEUCTICS FOR THE TREATMENT OF BENIGN AND NEOPLASTIC DISEASES, INFECTIONS, INFLAMMATORY, METABOLIC AND IMMUNOLOGIAL DISEASES | Escend Pharmaceuticals, Inc. | 2024-09-19 | — | — | US | disclosed |
| US-20240091238-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2005027843-A2 | CHRONOTHERAPEUTIC DOSAGE FORMS | PENWEST PHARMACEUTICALS CO. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1368005-A4 | CHRONOTHERAPEUTIC DOSAGE FORMS | PENWEST PHARMACEUTICALS CO (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004093850-A1 | TABLET WITH COLOURED CORE | JAGOTEC AG (CH) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093843-A1 | DELAYED RELEASE TABLET WITH DEFINED CORE GEOMETRY | JAGOTEC AG (CH) | 2004-11-04 | — | — | WO | disclosed |
| US-20040170684-A1 | For therapy of incontinence | PENWEST PHARMACEUTICALS CO. (US) | 2004-09-02 | — | — | US | disclosed |
| EP-1368005-A2 | CHRONOTHERAPEUTIC DOSAGE FORMS | Penwest Pharmaceuticals Co. (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030082230-A1 | Chronotherapeutic dosage forms and methods of treatment using chronotherapy | PENWEST PHARMACEUTICALS COMPANY | 2003-05-01 | — | — | US | disclosed |
| WO-2002072034-A2 | CHRONOTHERAPEUTIC DOSAGE FORMS | PENWEST PHAMACEUTICALS CO. (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-1135106-A1 | SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS | Edward Mendell Co., Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001022940-A1 | SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS | EDWARD MENDELL CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | NAPRT 169/4885KDM4E 714/4885ASPH 2511/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | NAPRT 169/4885KDM4E 714/4885ASPH 2511/4885 |
| US-20240091238-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CALM1, RACK1, CAMK2B | NAPRT 1771/4885KDM4E 1675/4885ASPH 2552/4885 |
| US-20250241928-A1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CALM1, RACK1, CAMK2B | NAPRT 1771/4885KDM4E 1675/4885ASPH 2552/4885 |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | NAPRT 1579/4885KDM4E 1059/4885ASPH 2936/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | NAPRT 210/4885KDM4E 1849/4885ASPH 282/4885 |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | NAPRT 1579/4885KDM4E 1059/4885ASPH 2936/4885 |
| US-12280064-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies | CALM1, RACK1, CAMK2B | NAPRT 1771/4885KDM4E 1675/4885ASPH 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.